Cancer Risk in Patients With Systemic Sclerosis: A Nationwide Cohort Study in South Korea 2004 to 2021
Arthritis Care & Research · 2025-12 · 77 (12) · 1466-1473
DOI: 10.1002/acr.25595 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Arthritis Care & Research, online erschienen am 23.09.2025. Verfasst von Jihyun Na und 4 weiteren Autor:innen. Beteiligte Einrichtung: Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea. Hauptthemen laut MEDLINE: Scleroderma, Systemic, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objective
Systemic sclerosis (SSc) is a rare autoimmune disease characterized by tissue fibrosis, vasculopathy, and immune dysregulation. Our objectives were to quantify the overall and site‐specific cancer risks in patients with SSc compared to the general population, examine temporal trends in cancer incidence following SSc diagnosis, and explore potential associations with immunosuppressive agent use.
Methods
Using data from the Korean National Health Insurance Service, we identified 6,386 patients newly diagnosed with SSc between 2004 and 2020. Standardized incidence ratios (SIRs) were calculated to compare the risk of cancer between patients with SSc and the general population. Subgroup analyses were performed based on age at diagnosis, follow‐up duration, and immunosuppressive agent use.
Results
Most patients (80.2%) were women, with a mean ± SD age at diagnosis of 53.1 ± 13.4 years. Patients with SSc had higher risks of overall cancer (SIR 3.12; 95% confidence interval [CI] 2.92–3.33), solid cancer (SIR 3.07; 95% CI 2.86–3.28), and hematologic cancer (SIR 5.70; 95% CI 4.50–7.11) compared to the general population. Myelodysplastic syndrome (SIR 12.52; 95% CI 7.00–20.65) had the highest risk, followed by multiple myeloma, eye, Hodgkin lymphoma, and larynx cancers. Cancer risk peaked among patients aged 20 to 39 years (SIR 5.27; 95% CI 4.31–6.38) and during the first year after diagnosis (SIR 4.44; 95% CI 3.81–5.14).
Conclusion
In this study, we revealed that the incidence of cancer is higher in patients with SSc in South Korea compared to the general population. The strong association between SSc and cancer occurrence prompts clinicians to conduct careful cancer screening for patients with SSc.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, South Korea.
- Hanmi Pharmaceutical, Co, Ltd, Seoul, South Korea.
ORCID-Profile: Jihyun Na, Su Jin Choi, Sojeong Park, Minae Park, Doo-Ho Lim
Zitieren
APA
Na, J., Choi, S. J., Park, S., Park, M., & Lim, D. H. (2025). Cancer Risk in Patients With Systemic Sclerosis: A Nationwide Cohort Study in South Korea 2004 to 2021. Arthritis Care & Research, 77(12), 1466-1473. https://doi.org/10.1002/acr.25595
Vancouver
Na J, Choi SJ, Park S, Park M, Lim DH. Cancer Risk in Patients With Systemic Sclerosis: A Nationwide Cohort Study in South Korea 2004 to 2021. Arthritis Care & Research. 2025;77(12):1466-1473. doi:10.1002/acr.25595
BibTeX
@article{Na2025,
author = {Na, Jihyun and Choi, Su Jin and Park, Sojeong and Park, Minae and Lim, Doo-Ho},
title = {Cancer Risk in Patients With Systemic Sclerosis: A Nationwide Cohort Study in South Korea 2004 to 2021},
journal = {Arthritis Care & Research},
year = {2025},
volume = {77},
number = {12},
pages = {1466--1473},
doi = {10.1002/acr.25595}
}
EUVIMED